Astellas Pharma Incorporated operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Astellas Pharma Incorporated with three other
companies in this sector in JAPAN :
Daiichi Sankyo Company Limited
sales of 981.79 billion Japanese Yen [US$9.27 billion]
of which 93%
was Prescription drugs),
Eisai Company Limited
(695.62 billion Japanese Yen [US$6.57 billion]
of which 83%
was Pharmaceutical Business), and
Shionogi & Co Ltd
(333.37 billion Japanese Yen [US$3.15 billion]
of which 100%
was Prescription Drugs related business).
Astellas Pharma Incorporated reported sales of ¥1.30 trillion (US$12.28 billion)
March of 2020.
decrease of 0.4%
versus 2019, when the company's sales were ¥1.31 trillion.
The sales level in 2020 was fairly close to the level five years ago: in 2015, Astellas Pharma Incorporated had sales
of ¥1.25 trillion.
Contributing to the drop in overall sales was the 52.8% decline
in Other Business, from ¥12.26 billion to ¥5.79 billion.
There were also decreases in sales in
Sales of Pharmaceuticals (down 0.1% to ¥1.26 trillion)
However, these declines were partially offset by the increase in sales of
Royalty (up 7.3% to ¥35.76 billion)